On Health Policy | Page 10 of 71 | National Center for Health Research

NCHR’s Comment on USPSTF’s Draft Recommendation Statement for Child Maltreatment: Primary Care Interventions

June 18, 2018. Given the burden of child maltreatment on our society’s children, it is critical to continuously evaluate any new evidence to find effective interventions that can prevent child maltreatment.

NCHR Comments on FDA’s Draft Guidance on Inclusion of Pregnant Women in Clinical Trials

June 8, 2018. We commend the FDA in its efforts to provide guidance on the inclusion of pregnant women in clinical trials. Currently, there is limited information regarding benefits and risks of drugs in pregnant women, including potential benefits and risks to the fetus.

NCHR Co-Signs Letter of Support for Patient Advocacy Transparency Act

March 8, 2018 The Honorable Claire McCaskill United States Senate 503 Hart Senate Office Building Washington, DC, 20510 Dear Senator McCaskill: We welcome the Patient Advocacy Transparency Act, which will expand the Physician Payments Sunshine Act to include disclosure of pharmaceutical and medical device company payments to advocacy organizations, professional societies, and other third parties. […]

NCHR Comment on USPSTF’s Draft Recommendation Statement Screening for Intimate Partner Violence and Elder Abuse

May 21, 2018. In conclusion, we agree with the USPSTF’s efforts to provide updated recommendations on screening of IPV and abuse based on quality, up-to-date studies. The benefits of screening for IPV for women outweigh the risks, and future studies should allow recommendations to be made for other populations. We agree with the USPSTF draft recommendation on IPV and elder abuse.

NCHR Comment on FDA’s Draft Guidance on Developing Drugs for Early Alzheimer’s Disease

May 16, 2018. We support the encouragement of research to develop drugs that would prevent or slow the progression of early Alzheimer’s disease (AD). We support the FDA’s recognition of the importance of efficacy endpoints that demonstrate a clinically meaningful effect on daily function and/or cognition for drug development. It is not appropriate to depend entirely on the use of biomarkers and of limited, narrow measures of neuropsychological performance. It will be important that when these newly developed drugs are evaluated for approval that the FDA maintains high standards for evidence that are based on sound science.